A comparative analysis revealed that ∆16HER activated the SRC pathway more effectively than HER2, while BrCa patients showing this genetic background received the greatest benefit from trastuzumab therapy [80]. This evidence concerns the gene ERBB2 and invasive breast carcinoma.